Filters








4,247 Hits in 1.6 sec

Psychiatry (2008 edn). By Lawrence J. Albers, Christopher Reist & Rhoda K. Hahn, Current Clinical Strategies Publishing. 2008. US$28.95 (CD-ROM for Palm, Pocket PC, Windows & Macintosh).∗ 115pp. ISBN: 9781934323038

Jeremy Clarkson
<span title="">2009</span> <i title="Royal College of Psychiatrists"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/r2ls53ulyfeynk6h7jbxyybana" style="color: black;">British Journal of Psychiatry</a> </i> &nbsp;
Albers, Christopher Reist & Rhoda K. Hahn Current Clinical Strategies Publishing. 2008. US$28.95 (CD-ROM for Palm, Pocket PC, Windows & Macintosh).* 115pp.  ... 
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1192/bjp.bp.108.060533">doi:10.1192/bjp.bp.108.060533</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/vwfp2fn4yzcoxi2wdd6oyy6zge">fatcat:vwfp2fn4yzcoxi2wdd6oyy6zge</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20190503004616/https://www.cambridge.org/core/services/aop-cambridge-core/content/view/C50B34D406E9CB31C3F70B63B26CB52F/S0007125000007637a.pdf/div-class-title-span-class-italic-psychiatry-2008-edn-span-by-lawrence-j-albers-christopher-reist-and-rhoda-k-hahn-current-clinical-strategies-publishing-2008-us-28-95-cd-rom-for-palm-pocket-pc-windows-and-macintosh-span-class-sup-span-115pp-isbn-9781934323038-div.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/ea/a6/eaa6cb8f566d5a6a3f34f9953fdb15194676b759.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1192/bjp.bp.108.060533"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> Publisher / doi.org </button> </a>

β-Adrenergic blockade and emotional memory in PTSD

Christopher Reist, John Gregory Duffy, Ken Fujimoto, Larry Cahill
<span title="">2001</span> <i title="Oxford University Press (OUP)"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/t7zhumcn45gvdefswsettbaxjm" style="color: black;">International Journal of Neuropsychopharmacology</a> </i> &nbsp;
Emotional arousal has been shown to enhance memory, an effect that is blocked by propranolol suggesting that the noradrenergic system is important in the mechanism action. Because PTSD has as prominent features heightened arousal and distressing memories, the current study was undertaken to examine whether PTSD subjects differed from controls in emotional enhancement of memory. Seventeen subjects with PTSD and 21 controls received either placebo or 40 mg of propranolol prior to exposure to
more &raquo; ... r an emotionally arousing or emotionally neutral, narrated slide story. Recall, measured 1 wk later, for the arousing story was enhanced and this effect was reduced by propranolol. PTSD and control subjects did not differ in the acquisition and retention of memories under emotionally arousing or emotionally neutral conditions, nor were differential effects of propranolol observed between the two groups.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1017/s1461145701002607">doi:10.1017/s1461145701002607</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/11806863">pmid:11806863</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/uefbwv5fynbgrcinpf7trz5vt4">fatcat:uefbwv5fynbgrcinpf7trz5vt4</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20170830084120/https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/ijnp/4/4/10.1017/S1461145701002607/2/4-4-377.pdf?Expires=1504132586&amp;Signature=el--V7Kssr4YbSnD9q-TmuVUT1z-AmktNJMK0A3MCVI6tSlNaVBxWQEI8KsofFOBaBBf8p1QGVWzx244u6y6YprG~w2ALw4bLHd22i82RzBszzj9O0N-f7K2gbCHB7wbN~P3tNHp1ZIunIg0ZEpOTzL5MK~fA7FRZ5e2kLc2le5f8DCGao-amVvomd6DRg8MOM2Vx5Caai4Mo1NxP5kT~H92s-NmLELMcArdQyB~MxUfwwVeVm3echLqRUk-I6GfrOvfNO9mFBNidTHr7FV6YzKzBD7CuAbc-1Lg8xG4SDZ9Tp9hg7uuzA4~41I815q3BJbzfn9nfeEgDu~HYMBXrQ__&amp;Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/19/23/1923c3727aa79a65229f877bdd57c14957ddda8e.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1017/s1461145701002607"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="unlock alternate icon" style="background-color: #fb971f;"></i> Publisher / doi.org </button> </a>

Shifting emphasis from pharmacogenomics to theragnostics

Vural Ozdemir, Bryn Williams-Jones, Stephen J Glatt, Ming T Tsuang, James B Lohr, Christopher Reist
<span title="">2006</span> <i title="Springer Nature"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/t2bqrmk7orfmxpqzqwiiyjwide" style="color: black;">Nature Biotechnology</a> </i> &nbsp;
Vural Ozdemir 1,2 , Bryn Williams-Jones 3 , Stephen J Glatt 4 , Ming T Tsuang 4 , James B Lohr 2,4,5 & Christopher Reist 1,2 © 2006 Nature Publishing Group http://www.nature.com/naturebiotechnology  ... 
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1038/nbt0806-942">doi:10.1038/nbt0806-942</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/16900136">pmid:16900136</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/rc73doyjqbch3kjpkvtqki4mnq">fatcat:rc73doyjqbch3kjpkvtqki4mnq</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20210718130423/https://www.nature.com/articles/nbt0806-942.pdf?error=cookies_not_supported&amp;code=f079335c-457d-46d7-86ab-f3a9a5e2cee4" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/c5/42/c5422f41354c41e45115eb5c7dbd2e124b0b4920.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1038/nbt0806-942"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> nature.com </button> </a>

Assessment of psychological pain in suicidal veterans

Christopher Reist, Steven Mee, Ken Fujimoto, Vivek Rajani, William E. Bunney, Blynn G. Bunney, JianJun Yang
<span title="2017-05-30">2017</span> <i title="Public Library of Science (PLoS)"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/s3gm7274mfe6fcs7e3jterqlri" style="color: black;">PLoS ONE</a> </i> &nbsp;
Psychological pain is a relatively understudied and potentially important construct in the evaluation of suicidal risk. Psychological pain also referred to as 'mental pain' or 'psychache' can be defined as an adverse emotional reaction to a severe trauma (e.g., the loss of a child) or may be associated with an illness such as depression. When psychological pain levels reach intolerable levels, some individuals may view suicide as the only and final means of escape. To better understand
more &raquo; ... ical pain, we previously developed and validated a brief self-rating 10-item scale, Mee-Bunney Psychological Pain Assessment Scale [MBP] in depressed patients and non-psychiatric controls. Our results showed a significant increase in psychological pain in the depressed patients compared to controls. We also observed a significant linear correlation between psychological pain and suicidality in the depressed patient cohort. The current investigation extends our study of psychological pain to a diagnostically heterogeneous population of 57 US Veterans enrolled in a suicide prevention program. In addition to the MBP, we administered the Columbia Suicide Severity Rating Scale (C-SSRS), Beck Depression Inventory (BDI-II), Beck Hopelessness Scale (BHS), and the Barratt Impulsiveness Scale (BIS-11). Suicidal patients scoring above a predetermined threshold for high psychological pain also had significantly elevated scores on all the other assessments. Among all of the evaluations, psychological pain accounted for the most shared variance for suicidality (C-SSRS). Stepwise regression analyses showed that impulsiveness (BIS) and psychological pain (MBP) contributed more to suicidality than any of the other combined assessments. We followed patients for 15 months and identified a subgroup (24/57) with serious suicide events. Within this subgroup, 29% (7/24) had a serious suicidal event (determined by the lethality subscale of the C-SSRS), including one completed suicide. Our results build upon our earlier findings and recent literature supporting psychological pain as a potentially important construct. Systematically evaluating psychological pain along with additional measures of suicidality could improve risk assessment and more effectively guide clinical resource allocation toward prevention.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1371/journal.pone.0177974">doi:10.1371/journal.pone.0177974</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/28558020">pmid:28558020</a> <a target="_blank" rel="external noopener" href="https://pubmed.ncbi.nlm.nih.gov/PMC5448740/">pmcid:PMC5448740</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/tyl6jnbkmfbgpi6cjqr3pzxzka">fatcat:tyl6jnbkmfbgpi6cjqr3pzxzka</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20190309005121/http://pdfs.semanticscholar.org/fc1e/b9044517d6e2443ba3c9a4dc527a06915dce.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/fc/1e/fc1eb9044517d6e2443ba3c9a4dc527a06915dce.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1371/journal.pone.0177974"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="unlock alternate icon" style="background-color: #fb971f;"></i> plos.org </button> </a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448740" title="pubmed link"> <button class="ui compact blue labeled icon button serp-button"> <i class="file alternate outline icon"></i> pubmed.gov </button> </a>

A study of psychological pain in substance use disorder and its relationship to treatment outcome [article]

Steven Mee, Blynn G. Bunney, Ken Fujimoto, John Penner, Garrett Seward, William E Bunney, Christopher Reist
<span title="2019-04-18">2019</span> <i title="Cold Spring Harbor Laboratory"> bioRxiv </i> &nbsp; <span class="release-stage" >pre-print</span>
Substance Use Disorder (SUD) is a major public health concern affecting an estimated 22.5 million individuals in the United States. The primary aim of this study was to characterize psychological pain in a cohort of patients participating in outpatient substance abuse treatment. A secondary aim was to determine the relationships between pre-treatment assessments of psychological pain, depression, anxiety and hopelessness with treatment retention time and completion rates. Data was analyzed from
more &raquo; ... 289 patients enrolled in an outpatient community drug treatment clinic that provides mental healthcare to the underserved. A previously determined threshold score on the Mee-Bunney Psychological Pain Assessment Scale (MBP) was utilized to group patients into high and low-moderate scoring subgroups. The higher pain group reported increased levels of anxiety, hopelessness and depression compared to those in the low-moderate pain group. Additionally, patients scoring in the higher psychological pain group exhibited reduced retention times in treatment and more than two-fold increased odds of dropout relative to patients with lower pre-treatment levels of psychological pain. Among all assessments, the correlation between psychological pain and treatment retention time was strongest. To our knowledge, this is the first study to demonstrate that psychological pain is an important construct that correlates with relevant clinical outcomes in substance abuse treatment. Further, pre-treatment screening for psychological pain may be of benefit in identifying higher-risk patients in need of targeted additional clinical resources to improve treatment retention and completion rates.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1101/613737">doi:10.1101/613737</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/tmznqigzgregpkjbjbq67rrwnu">fatcat:tmznqigzgregpkjbjbq67rrwnu</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20200710122656/https://www.biorxiv.org/content/biorxiv/early/2019/04/18/613737.full.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/20/11/2011d8cf7b5d343bfda49b5f7ca15f83e37d6c49.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1101/613737"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> biorxiv.org </button> </a>

Effectiveness of a Psychosocial Weight Management Program for Individuals with Schizophrenia

Noosha Niv, Amy N. Cohen, Alison Hamilton, Christopher Reist, Alexander S. Young
<span title="2012-03-20">2012</span> <i title="Springer Nature"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/zceop55qfzdbrhf33hyljmz3ti" style="color: black;">Journal of Behavioral Health Services &amp; Research</a> </i> &nbsp;
The objective of this study was to examine the effectiveness of a weight loss program for individuals with schizophrenia in usual care. The study included 146 adults with schizophrenia from two mental health clinics of the Department of Veterans Affairs. The 109 individuals who were overweight or obese were offered a 16-week, psychosocial, weight management program. Weight and Body Mass Index (BMI) were assessed at baseline, 1 year later, and at each treatment session. Only 51% of those who
more &raquo; ... overweight or obese chose to enroll in the weight management program. Participants attended an average of 6.7 treatment sessions, lost an eScholarship provides open access, scholarly publishing services to the University of California and delivers a dynamic research platform to scholars worldwide. average of 2.4 pounds, and had an average BMI decrease of 0.3. There was no significant change in weight or BMI compared to the control group. Intervention strategies that both improve utilization and yield greater weight loss need to be developed. Abstract The objective of this study was to examine the effectiveness of a weight loss program for individuals with schizophrenia in usual care. The study included 146 adults with schizophrenia from two mental health clinics of the Department of Veterans Affairs. The 109 individuals who were overweight or obese were offered a 16-week, psychosocial, weight management program. Weight and BMI were assessed at baseline, 1 year later and at each treatment session. Only 51% of those who were overweight or obese chose to enroll in the weight management program. Participants attended an average of 6.7 treatment sessions, lost an average of 2.4 pounds and had an average BMI decrease of 0.3. There was no significant change in weight or BMI compared to the control group. Intervention strategies that both improve utilization and yield greater weight loss need to be developed.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1007/s11414-012-9273-3">doi:10.1007/s11414-012-9273-3</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/22430566">pmid:22430566</a> <a target="_blank" rel="external noopener" href="https://pubmed.ncbi.nlm.nih.gov/PMC3809160/">pmcid:PMC3809160</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/lirzp4hzkvhmrbwn3ae6vazv7m">fatcat:lirzp4hzkvhmrbwn3ae6vazv7m</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20170816134405/http://escholarship.org/uc/item/9dj491zb.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/da/0e/da0ef0bd294b95a597608b795276cb3da017840e.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1007/s11414-012-9273-3"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> springer.com </button> </a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809160" title="pubmed link"> <button class="ui compact blue labeled icon button serp-button"> <i class="file alternate outline icon"></i> pubmed.gov </button> </a>

Implementation of Evidence-Based Employment Services in Specialty Mental Health

Alison B. Hamilton, Amy N. Cohen, Dawn L. Glover, Fiona Whelan, Eran Chemerinski, Kirk P. McNagny, Deborah Mullins, Christopher Reist, Max Schubert, Alexander S. Young
<span title="2013-10-21">2013</span> <i title="Wiley"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/x4ajhk4nf5bljjeedi7njbx7pm" style="color: black;">Health Services Research</a> </i> &nbsp;
Objective. Study a quality improvement approach for implementing evidence-based employment services at specialty mental health clinics. Data Sources/Study Setting. Semistructured interviews with clinicians and administrators before, during, and after implementation. Qualitative field notes, structured baseline and follow-up interviews with patients, semistructured interviews with patients after implementation, and administrative data. Study Design. Site-level controlled trial at four
more &raquo; ... ion and four control sites. Hybrid implementation-effectiveness study with mixed methods intervention evaluation design. Data Collection/Extraction Methods. Site visits, in-person and telephone interviews, patient surveys, patient self-assessment. A total of 801 patients completed baseline surveys and 53 clinicians and other clinical key stakeholders completed longitudinal qualitative interviews. Principal Findings. At baseline, sites varied in the availability, utilization, and quality of supported employment. Each site needed quality improvement for this service, though for differing reasons, with some needing development of the service itself and others needing increased service capacity. Improvements in knowledge, attitudes, beliefs, and referral behaviors were evident in mid-and postimplementation interviews, though some barriers persisted. Half of patients expressed an interest in working at baseline. Patients at implementation sites were 2.3 times more likely to receive employment services during the study year. Those who had a service visit were more likely to be employed at follow-up than those who did not. Conclusions. Studies of implementation and effectiveness require mixed methods to both enhance implementation in real time and provide context for interpretation of complex results. In this study, a quality improvement approach resulted in superior patient-level outcomes and improved clinician knowledge, attitudes, and behaviors, in the context of substantial variation among sites.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1111/1475-6773.12115">doi:10.1111/1475-6773.12115</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/24138608">pmid:24138608</a> <a target="_blank" rel="external noopener" href="https://pubmed.ncbi.nlm.nih.gov/PMC4097836/">pmcid:PMC4097836</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/duarlf5dmzfbzbqfaablabhowq">fatcat:duarlf5dmzfbzbqfaablabhowq</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20151213081012/https://www.researchgate.net/profile/Christopher_Reist/publication/258057982_Implementation_of_Evidence-Based_Employment_Services_in_Specialty_Mental_Health/links/5552359c08ae980ca606ab8b.pdf?inViewer=true&amp;disableCoverPage=true&amp;origin=publication_detail" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/08/ec/08ecb87b1b5e18ee8df549f74f1bfcbe292a9907.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1111/1475-6773.12115"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> Publisher / doi.org </button> </a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4097836" title="pubmed link"> <button class="ui compact blue labeled icon button serp-button"> <i class="file alternate outline icon"></i> pubmed.gov </button> </a>

Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol

Mark J. Sergi, Michael F. Green, Clifford Widmark, Christopher Reist, Stephen Erhart, David L. Braff, Kimmy S. Kee, Stephen R. Marder, Jim Mintz
<span title="">2007</span> <i title="American Psychiatric Publishing"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/dqvsfzghyzfq3bbad65qqfafui" style="color: black;">American Journal of Psychiatry</a> </i> &nbsp;
Objective: This stud y examined the short-term effects of first-and secondgeneration antipsychotic medications on social cognition and basic cognition. Method: One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol. Participants were administered multiple measures of social cognition, basic cognition, and clinical symptoms at baseline, the end of week 4, and the end of week 8. Seventy-three
more &raquo; ... ients completed the baseline assessment and at least one other assessment. Data were analyzed with mixed-effects analyses of covariance. For data reduction, the social cognitive measures were clustered into a summary score, and the cognitive measures were clustered into two summary scores: general cognitive ability and processing speed. (The effects on thinking of risperidone and olanzapine can be found at NCT00108368, www.clinicaltrials.gov.)
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1176/appi.ajp.2007.06091515">doi:10.1176/appi.ajp.2007.06091515</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/17898351">pmid:17898351</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/dgqga3oo7bfwpj6wiosapyup4e">fatcat:dgqga3oo7bfwpj6wiosapyup4e</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20170705070527/http://greenlab.npih.ucla.edu/Publications/CORT%20Tx%20Ms%20ecopy%20final.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/bd/bf/bdbf688166438fbc9b6b5d8d62901ef10d364c3f.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1176/appi.ajp.2007.06091515"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> Publisher / doi.org </button> </a>

Event-related Functional Magnetic Resonance Imaging of a Low Dose of Dexmedetomidine that Impairs Long-term Memory

Hiroki R. Hayama, Kristin M. Drumheller, Mark Mastromonaco, Christopher Reist, Lawrence F. Cahill, Michael. T. Alkire
<span title="">2012</span> <i title="Ovid Technologies (Wolters Kluwer Health)"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/cjmzhtkkdjgjphz5zuzahenz2a" style="color: black;">Anesthesiology</a> </i> &nbsp;
Work suggests the amnesia from dexmedetomidine (an α2-adrenergic agonist) is caused by a failure of information to be encoded into long-term memory and that dexmedetomidine might differentially affect memory for emotionally arousing material. We investigated these issues in humans using event-related neuroimaging to reveal alterations in brain activity and subsequent memory effects associated with drug exposure. Methods: Forty-eight healthy volunteers received a computer-controlled infusion of
more &raquo; ... ither placebo or low-dose dexmedetomidine (target = 0.15 ng/ml plasma) during neuroimaging while they viewed and rated 80 emotionally arousing (e.g., graphic war wound) and 80 nonarousing neutral (e.g., cup) pictures for emotional arousal content. Long-term picture memory was tested 4 days later without neuroimaging. Imaging data were analyzed for drug effects, emotional processing differences, and memory-related changes with statistical parametric mapping-8. Results: Dexmedetomidine impaired overall (mean ± SEM) picture memory (placebo: 0.58 ± 0.03 vs. dexmedetomidine: 0.45 ± 0.03, P = 0.001), but did not differentially modulate memory as a function of item arousal. Arousing pictures were better remembered for both groups. Dexmedetomidine had regionally heterogeneous effects on brain activity, primarily decreasing it in the cortex and increasing it in thalamic and posterior hippocampal regions. Nevertheless, a single subsequent memory effect for item memory common to both groups was identified only in the left hippocampus/ amygdala. Much of this effect was found to be larger for the placebo than dexmedetomidine group. Conclusion: Dexmedetomidine impaired long-term picture memory, but did not disproportionately block memory for emotionally arousing items. The memory impairment on dexmedetomidine corresponds with a weakened hippocampal subsequent memory effect. . Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. Anesthesiology's articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1097/aln.0b013e31826be467">doi:10.1097/aln.0b013e31826be467</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/22929730">pmid:22929730</a> <a target="_blank" rel="external noopener" href="https://pubmed.ncbi.nlm.nih.gov/PMC3482301/">pmcid:PMC3482301</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/oakcebrmzfb7toom3hcwtm24e4">fatcat:oakcebrmzfb7toom3hcwtm24e4</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20190223005551/http://pdfs.semanticscholar.org/3d11/2fd68c330230f95a4b4a4f8bbfba6bb46b33.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/3d/11/3d112fd68c330230f95a4b4a4f8bbfba6bb46b33.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1097/aln.0b013e31826be467"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> Publisher / doi.org </button> </a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482301" title="pubmed link"> <button class="ui compact blue labeled icon button serp-button"> <i class="file alternate outline icon"></i> pubmed.gov </button> </a>

A study of psychological pain in substance use disorder and its relationship to treatment outcome

Steven Mee, Blynn G. Bunney, Ken Fujimoto, John Penner, Garrett Seward, Keeley Crowfoot, William E. Bunney, Christopher Reist, Daniel J. Fridberg
<span title="2019-11-07">2019</span> <i title="Public Library of Science (PLoS)"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/s3gm7274mfe6fcs7e3jterqlri" style="color: black;">PLoS ONE</a> </i> &nbsp;
Substance Use Disorder (SUD) is a major public health concern affecting an estimated 22.5 million individuals in the United States. The primary aim of this study was to characterize psychological pain in a cohort of patients participating in outpatient treatment for SUD. A secondary aim was to determine the relationships between pre-treatment assessments of psychological pain, depression, anxiety and hopelessness with treatment retention time and completion rates. Data was analyzed from 289
more &raquo; ... ents enrolled in an outpatient community drug treatment clinic in Southern California, U.S. A previously determined threshold score on the Mee-Bunney Psychological Pain Assessment Scale (MBP) was utilized to group patients into high and low-moderate scoring subgroups. The higher pain group scored higher on measures of anxiety, hopelessness and depression compared to those in the low-moderate pain group. Additionally, patients scoring in the higher psychological pain group exhibited reduced retention times in treatment and more than two-fold increased odds of dropout relative to patients with lower pre-treatment levels of psychological pain. Among all assessments, the correlation between psychological pain and treatment retention time was strongest. To our knowledge, this is the first study to demonstrate that psychological pain is an important construct which correlates with relevant clinical outcomes in SUD. Furthermore, pre-treatment screening for psychological pain may help target higher-risk patients for clinical interventions aimed at improving treatment retention and completion rates.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1371/journal.pone.0216266">doi:10.1371/journal.pone.0216266</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/31697679">pmid:31697679</a> <a target="_blank" rel="external noopener" href="https://pubmed.ncbi.nlm.nih.gov/PMC6837512/">pmcid:PMC6837512</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/mqm34gnbfbf5fki2pye7vm5ocq">fatcat:mqm34gnbfbf5fki2pye7vm5ocq</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20201107090344/https://escholarship.org/content/qt7jv0h16x/qt7jv0h16x.pdf?t=qafdqc" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/c2/c3/c2c333e2a5361b0769f4454ad910b0750770d731.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1371/journal.pone.0216266"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="unlock alternate icon" style="background-color: #fb971f;"></i> plos.org </button> </a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837512" title="pubmed link"> <button class="ui compact blue labeled icon button serp-button"> <i class="file alternate outline icon"></i> pubmed.gov </button> </a>

Acupuncture for combat post-traumatic stress disorder: trial development and methodological approach for a randomized controlled clinical trial

Michael Hollifield, An-Fu Hsiao, Kala Carrick, Andrea Gory Munoz, Teresa Calloway, Karen Cocozza, Besa Smith, Tyler Smith, Tanja Jovanovic, Seth Norrholm, Estate Sokhadze, Christopher Reist
<span title="2021-09-06">2021</span> <i title="Springer Science and Business Media LLC"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/elawdhnd7neuxgmzbrr6efzkgu" style="color: black;">Trials</a> </i> &nbsp;
Background Post-traumatic stress disorder (PTSD) is a significant public health problem, affecting approximately 7% of the general population and 13–18% of the combat Veteran population. The first study using acupuncture for PTSD in a civilian population showed large pre- to post-treatment effects for an empirically developed verum protocol, which was equivalent to group cognitive behavior therapy and superior to a wait-list control. The primary objective of this study is to determine both
more &raquo; ... cal and biological effects of verum acupuncture for combat-related PTSD in treatment-seeking US Veterans. Methods This is a two-arm, parallel-group, prospective randomized placebo-controlled clinical trial. The experimental condition is verum acupuncture and the placebo control is sham (minimal) acupuncture in 1-h sessions, twice a week for 12 weeks. Ninety subjects will provide adequate power and will be allocated to group by an adaptive randomization procedure. The primary outcome is change in PTSD symptom severity from pre- to post-treatment. The secondary biological outcome is change from pre- to post-treatment in psychophysiological response, startle by electromyographic (EMG) eyeblink. Assessments will be conducted at pre-, mid-, post-, and 1-month post-treatment, blind to group allocation. Intent-to-treat analyses will be conducted. Discussion The study results will be definitive because both clinical and biological outcomes will be assessed and correlated. Issues such as the number needed for recruitment and improvement, use of sham acupuncture, choice of biological measure, and future research need will be discussed. Trial registration ClinicalTrials.gov NCT02869646. Registered on 17 August 2016.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1186/s13063-021-05394-3">doi:10.1186/s13063-021-05394-3</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/34488824">pmid:34488824</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/77dcprcecndvfilf4cswkznicu">fatcat:77dcprcecndvfilf4cswkznicu</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20210907044340/https://trialsjournal.biomedcentral.com/track/pdf/10.1186/s13063-021-05394-3.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/2a/39/2a399655fda8c4cac0bdda8ca7d92e98ed943c70.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1186/s13063-021-05394-3"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="unlock alternate icon" style="background-color: #fb971f;"></i> springer.com </button> </a>

Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: A double-blind, randomized controlled trial

Jonathan K. Wynn, Michael F. Green, Joyce Sprock, Gregory A. Light, Clifford Widmark, Christopher Reist, Stephen Erhart, Stephen R. Marder, Jim Mintz, David L. Braff
<span title="">2007</span> <i title="Elsevier BV"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/n2tjigm4ejgmpavxgi3mqsqsfe" style="color: black;">Schizophrenia Research</a> </i> &nbsp;
Reist has consulted for Johnson and Johnson.  ... 
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1016/j.schres.2007.05.039">doi:10.1016/j.schres.2007.05.039</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/17662577">pmid:17662577</a> <a target="_blank" rel="external noopener" href="https://pubmed.ncbi.nlm.nih.gov/PMC2716219/">pmcid:PMC2716219</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/3hwli354qncrrohnqy6d3we3cy">fatcat:3hwli354qncrrohnqy6d3we3cy</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20170808195330/http://greenlab.npih.ucla.edu/Publications/Wynn%20et%20al%202007%20ppi%20drug%20sz.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/af/d2/afd2c8c484ef0ccab254e43ba8c4ea6bcf5c2d92.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1016/j.schres.2007.05.039"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> elsevier.com </button> </a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716219" title="pubmed link"> <button class="ui compact blue labeled icon button serp-button"> <i class="file alternate outline icon"></i> pubmed.gov </button> </a>

Gd-BOPTA Transport Into Rat Hepatocytes: Pharmacokinetic Analysis of Dynamic Magnetic Resonance Images Using a Hollow-Fiber Bioreactor

Corinne Planchamp, Marianne Gex-Fabry, Christophe Dornier, Rafael Quadri, Marianne Reist, Marko K. Ivancevic, Jean-Paul Vall??e, Sibylle Pochon, Fran??ois Terrier, Luc Balant, Bruno Stieger, Peter J. Meier (+1 others)
<span title="">2004</span> <i title="Ovid Technologies (Wolters Kluwer Health)"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/4qrvn236tzhfhoegnbrbdxcgxe" style="color: black;">Investigative Radiology</a> </i> &nbsp;
Rationale and Objectives: To investigate the transport of the hepatobiliary magnetic resonance (MR) imaging contrast agent Gd-BOPTA into rat hepatocytes. Materials and Methods: In a MR-compatible hollow-fiber bioreactor containing hepatocytes, MR signal intensity was measured over time during the perfusion of Gd-BOPTA. For comparison, the perfusion of an extracellular contrast agent (Gd-DTPA) was also studied. A compartmental pharmacokinetic model was developed to describe dynamic signal
more &raquo; ... ty-time curves. Results: The dynamic signal intensity-time curves of the hepatocyte hollow-fiber bioreactor during Gd-BOPTA perfusion were adequately fitted by 2 compartmental models. Modeling permitted to discriminate between the behaviors of the extracellular contrast agent (Gd-DTPA) and the hepatobiliary contrast agent (Gd-BOPTA). It allowed the successfully quantification of the parameters involved in such differences. Gd-BOPTA uptake was saturable at high substrate concentrations. Conclusions: The transport of Gd-BOPTA into rat hepatocytes was successfully described by compartmental analysis of the signal intensity recorded over time and supported the hypothesis of a transporter-mediated uptake.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1097/01.rli.0000129156.16054.30">doi:10.1097/01.rli.0000129156.16054.30</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/15257212">pmid:15257212</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/2pbm5sitbbakpbbpw36nxrenau">fatcat:2pbm5sitbbakpbbpw36nxrenau</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20201107082400/https://archive-ouverte.unige.ch/files/downloads/0/0/0/4/2/5/2/4/unige_42524_attachment01.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/0b/7b/0b7bcd6031a53fd4b45c524ef8195f3a07ffcd5e.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1097/01.rli.0000129156.16054.30"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> Publisher / doi.org </button> </a>

Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery DiseaseClinical Perspective

W. Schuyler Jones, Iris Baumgartner, William R. Hiatt, Gretchen Heizer, Michael S. Conte, Christopher J. White, Jeffrey S. Berger, Peter Held, Brian G. Katona, Kenneth W. Mahaffey, Lars Norgren, Juuso Blomster (+4 others)
<span title="2016-11-13">2016</span> <i title="Ovid Technologies (Wolters Kluwer Health)"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/yp7myvwge5ef7jsub32vmdbdhy" style="color: black;">Circulation</a> </i> &nbsp;
BACKGROUND: In patients with symptomatic peripheral artery disease with a history of limb revascularization, the optimal antithrombotic regimen for longterm management is unknown. METHODS: The EUCLID trial (Examining Use of Ticagrelor In PAD) randomized 13 885 patients with peripheral artery disease to treatment with ticagrelor 90 mg twice daily or clopidogrel 75 mg daily. Patients were enrolled based on an abnormal ankle-brachial index ≤0.80 or a previous lower extremity revascularization.
more &raquo; ... analysis focuses on the 7875 (57%) patients enrolled based on the previous lower extremity revascularization criterion. Patients could not be enrolled within 30 days of most recent revascularization, and patients with an indication for dual antiplatelet therapy were excluded. The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. RESULTS: Patients with a previous revascularization had a mean age of 66 years, 73% were male, and the median baseline ankle-brachial index was 0.78. After adjustment for baseline characteristics, patients enrolled based on previous revascularization had similar rates of the primary composite end point (hazard ratio [HR] 1.10, 95% confidence interval [CI] 0.98-1.23, P=0.12) and statistically significantly higher rates of myocardial infarction (HR 1.29, 95% CI 1.08-1.55, P=0.005) and acute limb ischemia (HR 4.23, 95% CI 2.86-6.25, P<0.001) when compared with patients enrolled based on ankle-brachial index criteria. No differences in ticagrelor-versus clopidogrel-treated patients were found for the primary efficacy end point (11.4% vs 11.3%; HR 1.01, 95% CI 0.88-1.15; P=0.90), all-cause mortality (9.2% vs 9.2%; HR 0.99, 95% CI 0.86-1.15; P=0.93), acute limb ischemia (2.5% vs 2.5%; HR 1.03, 95% CI 0.78-1.36; P=0.84), or major bleeding (1.9% vs 1.8%; HR 1.15, 95% CI 0.83-1.59; P=0.41). The median duration of follow-up was ≈30 months. CONCLUSIONS: After adjustment for baseline characteristics, patients enrolled based on previous revascularization for peripheral artery disease had higher rates of myocardial infarction and acute limb ischemia, with similar composite rates of cardiovascular death, myocardial infarction, and stroke when compared with patients enrolled based on the ankle-brachial index criterion. No significant differences were found between ticagrelor and clopidogrel for reduction of cardiovascular or acute limb events.
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1161/circulationaha.116.025880">doi:10.1161/circulationaha.116.025880</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/27840336">pmid:27840336</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/k7m34agoobe2jkiqdfihnrloke">fatcat:k7m34agoobe2jkiqdfihnrloke</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20190217072622/http://pdfs.semanticscholar.org/042e/a2a671077003586f9e11e22d8268d3e5c029.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/04/2e/042ea2a671077003586f9e11e22d8268d3e5c029.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1161/circulationaha.116.025880"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> Publisher / doi.org </button> </a>

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome

Sabina A. Murphy, Christopher P. Cannon, Michael A. Blazing, Robert P. Giugliano, Jennifer A. White, Yuliya Lokhnygina, Craig Reist, KyungAh Im, Erin A. Bohula, Daniel Isaza, Jose Lopez-Sendon, Mikael Dellborg (+3 others)
<span title="">2016</span> <i title="Elsevier BV"> <a target="_blank" rel="noopener" href="https://fatcat.wiki/container/ssdz5shjvrai3ijjkutdhctqam" style="color: black;">Journal of the American College of Cardiology</a> </i> &nbsp;
BACKGROUND Intensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) significantly reduced the first primary endpoint (PEP) in patients post-acute coronary syndrome (ACS) compared to placebo/simvastatin. OBJECTIVES This analysis tested the hypothesis that total events, including those beyond the first event, would also be reduced with ezetimibe/simvastatin therapy. METHODS All PEP events
more &raquo; ... cardiovascular [CV] death, myocardial infarction [MI], stroke, unstable angina [UA] leading to hospitalization, coronary revascularization $30 days post-randomization) during a median 6-year follow-up were analyzed in patients randomized to receive ezetimibe/simvastatin or placebo/simvastatin in IMPROVE-IT. Negative binomial regression was used for the primary analysis. RESULTS Among 18,144 patients, there were 9,545 total PEP events (56% were first events and 44% subsequent events). Total PEP events were significantly reduced by 9% with ezetimibe/simvastatin vs placebo/simvastatin (incidence-rate ratio [RR]: 0.91; 95% confidence interval [CI]: 0.85 to 0.97; p ¼ 0.007), as were the 3 pre-specified secondary composite endpoints and the exploratory composite endpoint of CV death, MI, or stroke (RR: 0.88; 95% CI: 0.81 to 0.96; p ¼ 0.002). The reduction in total events was driven by decreases in total nonfatal MI (RR: 0.87; 95% CI: 0.79 to 0.96; p ¼ 0.004) and total NF stroke (RR: 0.77; 95% CI: 0.65 to 0.93; p ¼ 0.005). CONCLUSIONS Lipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes. Reductions in total PEP events, driven by reductions in MI and stroke, more than doubled the number of events prevented compared with examining only the first event. These data support continuation of intensive combination lipid-lowering therapy after an initial CV event. (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT]; NCT00202878) (J Am Coll Cardiol 2016;67:353-61)
<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1016/j.jacc.2015.10.077">doi:10.1016/j.jacc.2015.10.077</a> <a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/26821621">pmid:26821621</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/yrk5mnwfh5emfe3q6d5ei3chaq">fatcat:yrk5mnwfh5emfe3q6d5ei3chaq</a> </span>
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20190419112553/https://core.ac.uk/download/pdf/82088780.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/f9/4f/f94fabbf781da56c1d8478e4867fb612098d7a87.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1016/j.jacc.2015.10.077"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> elsevier.com </button> </a>
&laquo; Previous Showing results 1 &mdash; 15 out of 4,247 results